Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefurock is a branded generic formulation of the second-generation cephalosporin antibiotic cefuroxime, marketed by El-Dorado Biotech (Eldora). As a beta-lactam antibiotic, it exerts bactericidal activity by binding to and inhibiting penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding disrupts the final transpeptidation step of peptidoglycan synthesis, which is essential for bacterial cell wall integrity, ultimately leading to cell lysis and death. Cefurock is effective against a broad spectrum of Gram-positive and Gram-negative bacteria and is typically indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and certain sexually transmitted diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cefurock.